Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CRBN | Q96SW2 | 16/20 | 0.60 |
| ▸ | IKZF2 | Q9UKS7 | 4/20 | 0.55 |
| ▸ | IKZF1 | Q13422 | 2/20 | 0.55 |
| ▸ | BRD4 | O60885 | 1/20 | 0.48 |
| ▸ | TNF | P01375 | 1/20 | 0.48 |
| ▸ | IL1B | P01584 | 1/20 | 0.48 |
| ▸ | DDB1 | Q16531 | 1/20 | 0.48 |
| ▸ | IKZF3 | Q9UKT9 | 1/20 | 0.48 |
| ▸ | CSNK1A1 | P48729 | 1/20 | 0.47 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29450095 | 1.00 | CRBN (0.60) | CRBNIKZF2IKZF1BRD4TNF | |
| SCHEMBL31116980 | 1.00 | CRBN (0.60) | CRBNIKZF2IKZF1BRD4TNF | |
| Hydrochloric Acid SCHEMBL30496965 | 0.99 | CRBN (0.58) | CRBNIKZF2IKZF1BRD4TNF | |
| Hydrochloric Acid SCHEMBL25234527 | 0.99 | CRBN (0.58) | CRBNIKZF2IKZF1BRD4TNF | |
| SCHEMBL30373108 | 0.95 | CRBN (0.60) | CRBNIKZF2IKZF1BRD4TNF | |
| SCHEMBL26131967 | 0.95 | CRBN (0.60) | CRBNIKZF2IKZF1BRD4TNF | |
| SCHEMBL23876476 | 0.90 | CRBN (0.64) | CRBNIKZF2IKZF1 | |
| SCHEMBL25230229 | 0.89 | CRBN (0.60) | CRBNIKZF2IKZF1DDB1CSNK1A1 | |
| SCHEMBL30460119 | 0.89 | CRBN (0.60) | CRBNIKZF2IKZF1DDB1CSNK1A1 | |
| SCHEMBL25236602 | 0.89 | CRBN (0.60) | CRBNIKZF2IKZF1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4446324-A1 | LIGAND COMPOUNDS FOR E3 UBIQUITIN LIGASE, PROTEIN DEGRADERS DEVELOPED ON BASIS OF LIGAND COMPOUNDS, AND USES THEREOF | Gluetacs Therapeutics (Shanghai) Co., Ltd. (CN) | 2024-10-16 | — | — | EP | claimed |
| WO-2023104155-A1 | LIGAND COMPOUNDS FOR E3 UBIQUITIN LIGASE, PROTEIN DEGRADERS DEVELOPED ON BASIS OF LIGAND COMPOUNDS, AND USES THEREOF | 标新生物医药科技(上海)有限公司 | 2023-06-15 | — | — | WO | claimed |
| CN-116239566-A | E3 ubiquitin ligase ligand compound, protein degradation agent developed based on ligand compound and application thereof | 标新生物医药科技(上海)有限公司 | 2023-06-09 | — | — | CN | claimed |
| US-20240294489-A1 | LOW MOLECULAR WEIGHT PROTEIN DEGRADERS AND THEIR APPLICATIONS | CAPTOR THERAPEUTICS S.A. (PL) | 2024-09-05 | — | — | US | disclosed |
| CN-116457344-A | Low molecular weight protein degradation agent and application thereof | 凯普托尔治疗学股份有限公司 | 2023-07-18 | — | — | CN | disclosed |
| WO-2023104155-A1 | LIGAND COMPOUNDS FOR E3 UBIQUITIN LIGASE, PROTEIN DEGRADERS DEVELOPED ON BASIS OF LIGAND COMPOUNDS, AND USES THEREOF | 标新生物医药科技(上海)有限公司 | 2023-06-15 | — | — | WO | disclosed |
| EP-4188373-A1 | LOW MOLECULAR WEIGHT PROTEIN DEGRADERS AND THEIR APPLICATIONS | Captor Therapeutics S.A. (PL) | 2023-06-07 | — | — | EP | disclosed |
| WO-2022029138-A1 | LOW MOLECULAR WEIGHT PROTEIN DEGRADERS AND THEIR APPLICATIONS | CAPTOR THERAPEUTICS S.A. (PL) | 2022-02-10 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20240294489-A1 | LOW MOLECULAR WEIGHT PROTEIN DEGRADERS AND THEIR APPLICATIONS | MMP2, PSME2, PSME1 | CRBN 251/4885IKZF2 1953/4885IKZF1 1095/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.